NW-3509 – First voltage-gated sodium channel blocker as add-on therapy for the treatment of schizophrenia. MILAN–(BUSINESS WIRE)–December 2, 2015–. Newron Pharmaceuticals S.p.A. (“Newron”), a research and …
Newron Initiates U.S. Phase II Trial in Patients with Schizophrenia …
